|  |
| --- |
| Delete and replace with your institution/site logo. Image height should be at most 0.80. Make sure image settings are set to "Lock aspect ratio" to prevent warping. |
| **The EA8191/INDICATE Trial**  Phase III Study of Local or Systemic Therapy INtensification DIrected by PET in Prostate CAncer Patients With Post-ProstaTEctomy Biochemical Recurrence  The INDICATE trial is a phase III study testing treatments for prostate cancer patients who have a rise in PSA levels after surgery. It has two separate comparisons of therapies: the first compares standard therapy (radiation and short-term hormone therapy) to an enhanced therapy that adds apalutamide. The second part focuses on patients with cancer spread detected by PET scans, testing if adding targeted radiation to the enhanced therapy improves outcomes. The goal of the study is to determine if these enhanced approaches help prevent cancer recurrence and improve survival.  Scan the QR Code with your phone to watch a short video series explaining:  prostate cancer, PSA, PET scan, and the INDICATE Trial.  Video Link: [www.primrmed.com/cancer-clinical-trials/indicate-trial](http://www.primrmed.com/cancer-clinical-trials/indicate-trial)  Trial Home Page: <https://ecog-acrin.org/clinical-trials/ea8191-indicate-prostate-cancer/>   |  |  |  | | --- | --- | --- | | **INDICATE**  PART I  Introduction |  | Scan to watch Part I | | **INDICATE**  PART II  PET-negative Group |  | Scan to watch Part II | | **INDICATE**  PART III  PET-positive Group |  | Scan to watch Part III | |

